HIV POST-EXPOSURE PROPHYLAXIS (PEP) TREATMENT

The human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) starter kits are provided by the Saskatchewan Health Authority. These starter kits are located in a variety of health care facilities throughout Saskatchewan. The starter kits contain tenofovir disoproxil fumarate/emtricitabine, tablet 200mg/300mgand dolutegravir, tablet 50 mg for 5 days of treatment. The remaining course of this combination of medications can be obtained with a prescription from a health care provider authorized to prescribe. Pharmacies can then submit the remainder of the HIV PEP prescription claim (i.e., up to 23 days supply of the PEP medication) to the Drug Plan for coverage at no cost to the patient.

The Drug Plan authorizes funding for the following drugs as noted below for HIV post-exposure prophylaxis (PEP):

Regimen 1: dolutegravir, tablet, 50mg (Tivicay) and emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada, and listed generics)[1]

The Drug Plan authorizes Exception Drug Status (EDS) for the additional regimens as listed below for post-exposure prophylaxis (PEP):

Regimen 2: emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada and listed generics) and raltegravir, tablet, 400mg (Isentress)
When prescribed by, or on the advice of an Infectious Disease specialist or other HIV authorized prescriber familiar with HIV treatment, for PEP.

The following are alternatives to complete 28 days HIV PEP in special circumstances:

Regimen 3: darunavir, tablet, 800mg (Prezista), ritonavir, tablet, 100mg (Norvir) and emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada and listed generics)[1]
When prescribed by, or on the advice of an Infectious Disease specialist or other HIV authorized prescriber familiar with HIV treatment, for post-exposure prophylaxis (PEP).

Regimen 4: lamivudine/zidovudine, tablet, 150mg/300mg (Combivir) and lopinavir/ritonavir, tablet, 200mg/50mg (Kaletra)
When prescribed by, or on the advice of an Infectious Disease specialist or other HIV authorized prescriber familiar with HIV treatment, for post-exposure prophylaxis (PEP).

To receive approval for the coverage of any Exception Drug Status (EDS) medications included in the HIV PEP treatment regimens, pharmacies will submit a prescription claim through the Drug Plan network for Drug Plan beneficiaries.

[1] emtricitabine/tenofovir disoproxil fumarate and dolutegravir are full Formulary benefits and would not require EDS approval

a) If the prescriber is an approved HIV prescriber, Exception Drug Status (EDS) is automatically approved through online EDS adjudication (OEA).

b) If the prescriber is not an approved HIV prescriber, the pharmacist calls the Drug Plan for approval and will indicate “HIV PEP medication in consultation with ID specialist”. The Drug Plan will approve the EDS coverage.

The Saskatchewan Guidelines for the Management of Exposures to Blood and Body Fluids are available at the following link: https://www.ehealthsask.ca/services/Manuals/Pages/hiv-guidelines.aspx